<DOC>
	<DOCNO>NCT00732212</DOCNO>
	<brief_summary>The main purpose study compare clinical outcome two group patient similar medical condition ( one non-variceal UGI lesions ulcer another group varices portal hypertensive lesion ) treat either current standard visually guide endoscopic treatment accord stigmata hemorrhage endoscopic Doppler endoscopic ultrasound probe ( DEP ) monitoring blood flow lesion .</brief_summary>
	<brief_title>Doppler Ultrasound Probe Blood Flow Detection Severe Upper Gastrointestinal Hemorrhage</brief_title>
	<detailed_description>Background : For patient severe upper gastrointestinal ( UGI ) hemorrhage , risk stratification rebleeding endoscopic hemostasis base visually define endoscopic stigma hemorrhage 40 year . These imperfect , significant interobserver variation investigator previously unable detect underlie vessel blood flow , directly relate risk rebleeding . Doppler ultrasound endoscopic probe ( DEP ) relatively new US detect underlie lesion blood flow . However , patient severe UGI hemorrhage study endoscopic doppler ultrasound probe US none VA 's . The CURE/VA GI Hemostasis Research Group perform prospective randomize study West Los Angeles VA University California Los Angeles ( UCLA ) Ronald Reagan Medical Centers define role Doppler ultrasound probe ( DUP ) management severe UGI hemorrhage . Objectives : The specific aim ( SA ) research : # 1 ) In randomize , blind prospective control ( RCT ) study patient severe UGI hemorrhage ( varices/portal hypertensive lesion one separate group vs. ulcer , &amp; benign non-variceal source another group ) compare 30 day outcomes patient 2 major disease group - Non-variceal &amp; Variceal-Portal hypertension lesion manage current standard ( accord endoscopic visualization &amp; stigma hemorrhage ) similar patient assess , risk stratify , &amp; treat DEP monitoring . # 2 ) . For patient randomized DEP group , determine initial prevalence , type ( arterial venous ) , &amp; location &amp; course blood flow underlie stigmata different lesion group . # 3 ) . For DEP patient different lesion type , determine rate persistent blood flow endoscopic hemostasis treatment &amp; whether blood flow stigma eliminate endoscopic hemostasis different technique . # 4 ) . To determine proportion patient whose risk stratification ( rebleeding ) &amp; /or endoscopic treatment change utilizing DEP detection blood flow stigma hemorrhage lesion guide endoscopic treatment &amp; absence flow treatment treatment endpoint rather visual guideline ( stigma ) alone endoscopic treatment . # 5 ) . To compare outcomes large cohort historical control previously treat hemostasis two lesion type UGI tract CURE/VA Hemostasis Research Group accord visual guideline &amp; stigma alone patient RCT manage DUP finding &amp; stigma , contrast demographic , hemostasis rate , rebleeding rate &amp; outcomes 30 day major diagnosis ( ulcer non-variceal lesion v varix &amp; lesion related portal hypertension ) . # 6 ) . For patient treat surgery angiography continue bleed rebleeding UGI lesion , correlate &amp; compare vessel depth &amp; location ( relative stigma ) , type vessel , &amp; lumen patency surgery angiography vs. Doppler endoscopic probe finding record previously . Research Plan Methods : All study perform 5 year . The investigator utilize large RCT ( blind ) , large cohort study , &amp; prospective observational study complete specific aim study . SAS utilize data management . For SA # 1 , 240 new patient ( 150 non-variceal lesion 90 variceal-portal hypertensive lesion ) admit West Los Angeles ( WLA ) VA UCLA Hospitals severe UGI hemorrhage randomize RCT Doppler assist management versus standard endoscopic/medical diagnosis , risk stratification , &amp; treatment . During urgent endoscopy , patient clean varix ( source bleeding ) UGI lesion stigmata recent hemorrhage ( ulcer , Mallory Weiss tear , esophageal gastric varix , Dieulafoy 's lesion ) randomize . Routine clinical outcome assess prospectively &amp; compare major diagnostic group ( ulcers-non-variceal lesion varices-portal hypertensive lesion ) . For SA # 5 ( UGI cohort study ) , demographic , outcome , &amp; risk factor compare 150 patient non-variceal lesion &amp; 90 variceal-portal hypertensive lesion match historical control patient ( CURE Hemostasis Research Databases ) treat previously base upon stigma vs. 75 new patient non-variceal UGI lesion 50 variceal-portal hypertension lesion study treat accord stigma hemorrhage &amp; DEP guide risk stratification &amp; endoscopic hemostasis . SA # 2-4 &amp; 6 prospectively perform accord method proposal &amp; analysis perform collaboration experience biostatistician . Potential Impact Veterans Non- VA Healthcare : These study increase investigator ' knowledge UGI bleeding , UGI lesion vasculature , blood flow , effect endoscopic hemostasis . Also , DEP may improve risk stratification Veteran patient , medical endoscopic management &amp; outcomes patient severe UGI hemorrhage different etiology . This particularly relevant patient care Veterans severe UGI hemorrhage , since common clinical condition require considerable health care resource every VA hospital . These result also generalizable non-VA hospital US population hospitalize severe UGI bleeding .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Gastrointestinal Hemorrhage</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>Patients must evidence severe UGI bleed laboratory test ( Hgb le equal 9 gm ; RBC transfusion ; document decrease Hgb great equal 2 gm relative baseline ) clinical parameter ( melena ; hematemesis hematochezia ; nasogastric tube ( NG ) evidence UGI bleed fresh blood , clot , old blood ) . The following nonvariceal UGI lesion include stigmata hemorrhage find emergency endoscopy ( active arterial bleeding , ooze , nonbleeding visible vessel ( NBVV ) , adherent clot , flat spot combination ) peptic ulcer ( gastric , duodenal , esophageal , anastomatic ) , MalloryWeiss ( MW ) tear without portal hypertension ( PHTN ) , Dieulafoy 's lesion . For type severe UGI bleeding related PHTN , investigator also include patient esophageal gastric varix ( without stigma , UGI lesion source bleed ) ; postrubber band ligation ( RBL ) ulcer , MW tear associate PHTN stigma recent hemorrhage . Life expectancy least 60 day base lack severe terminal comorbidity , judged generalist specialist care patient . Written informed consent patient surrogate . Patients uncooperative , unable give write informed consent , return 30 day followup , refuse inform consent . Patients UGI know malignancy malignant appear ulcer ; diffuse bleed mucosal lesion esophagitis ; infectious UGI lesion ; bleed lesion ( polyp , postendoscopic mucosal resection ( EMR ) , postsphincterotomy ) . Endstage , severe , recurrent ongoing comorbid illness , e.g . severe liver , renal , cardiac , respiratory failure ; peritonitis ; sepsis preclude emergency procedure clinical followup limit survival . Persistent shock hypotension ( e.g . systolic blood pressure less equal 99 mm mercury ) unresponsive less equal 6 unit pack red blood cell ( RBC ) transfusion require continuous intravenous infusion vasoactive drug blood pressure elevation . Severe coagulopathy unresponsive blood transfusion e.g . international normalized ratio ( INR ) &gt; 2.0 , platelet count &lt; 20,000 , activate partial thromboplastin time ( APTT ) great 2.0 x normal , bleeding time &gt; 10 minute . Contraindication urgent endoscopy followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>UGI Bleeding</keyword>
	<keyword>Ulcer variceal hemorrhage</keyword>
	<keyword>Stigmata recent hemorrhage</keyword>
	<keyword>Endoscopy</keyword>
	<keyword>Randomized Controlled Trial</keyword>
	<keyword>Non-variceal UGI hemorrhage</keyword>
	<keyword>Variceal hemorrhage</keyword>
</DOC>